Bruce Bent - 14 Jun 2022 Form 3 Insider Report for Heart Test Laboratories, Inc. (HSCS)

Role
Director
Signature
/s/ Mark Hilz, Attorney-In-Fact
Issuer symbol
HSCS
Transactions as of
14 Jun 2022
Net transactions value
$0
Form type
3
Filing time
07 Jul 2022, 17:21:31 UTC
Previous filing
16 Aug 2021
Next filing
22 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding HSCS Common Stock 1,638 14 Jun 2022 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HSCS Director Stock Option (Right to Buy) 14 Jun 2022 Common Stock 1,894 $3.47 Direct F1
holding HSCS Director Stock Option (Right to Buy) 14 Jun 2022 Common Stock 1,894 $3.47 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The entire option has become fully-vested and may be exercised at any time at the Holder's election.
F2 The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied.